Overview

Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

Status:
Unknown status

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).

Phase:

N/A

Details

Lead Sponsor:

Centre of Postgraduate Medical Education

Treatments:

Dabigatran
Enoxaparin
Rivaroxaban